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To the Editor, 
  There is growing interest in the potential of mesenchymal stem cells (MSCs) as a therapy for 
the acute respiratory distress syndrome (ARDS). Phase I studies have been reported (1, 2), 
while a larger phase II study has recently completed recruitment (NCT02097641). Several 
more are underway (NCT02611609, NCT03042143, NCT02804945). However, these trials 
have excluded patients supported by extracorporeal membrane oxygenation (ECMO), which is 
increasingly used in patients with severe ARDS (3). While the use of MSCs during ECMO has 
been described in case reports (4), the compatibility of MSCs and ECMO has not been 
systematically evaluated. Here, we present data to suggest that the intravascular administration 
of MSCs during ECMO may have consequences for oxygenator function.  
Methods 
  The study was approved by the Metro North Ethics Committee (HREC/16/QPCH/221). Ex-
vivo ECMO was conducted based on our previously described simulated model (5). Briefly, 
permanent life support (PLS) circuits (Maquet, Germany) incorporating, a Quadrox D 
Oxygenator, a RotaFlow pump, and Bioline™ tubing, were used. Circuits were primed with 
500 mL 0.9% sodium chloride (Baxter, Australia), after which, this was exchanged for fresh 
human whole blood (final volume, 420 ± 50 mL). Circulation was commenced at 2000 rpm, 
using a smooth transition clamp to provide a resistance permitting a blood flow of 4 L min-1. 
After baseline sampling, 10 mL of calcium chloride (CSL, Australia), 12 mL of 8.4% sodium 
bicarbonate (Baxter), and 400 units of sodium heparin (Pfizer, Australia), were added to the 
circuit to achieve a pH between 7.3 – 7.5 and an activated clotting time (ACT) ≥ 180 seconds. 
Pressure across the oxygenator was measured using a silicone based pressure transducer 
(Omega Engineering, USA). Circulating blood temperature was maintained at 37 ± 0.5 °C. A 
solution of saline, adenine, glucose, and mannitol (MacoPharma, Australia) was infused at a 
rate of 4 mL hr-1 to ensure pressure equilibrium within the circuit. Fresh gas flow was set at 2.5 
L min-1 (5% CO2, 21% O2, 74% N2).  
  Clinical-grade induced pluripotent stem cell (iPSC) derived human MSCs (Cynata 
Therapeutics Ltd., Australia) were obtained and stored in the vapor-phase of liquid nitrogen 
until use. Cells were suspended in a vehicle composed of Plasmalyte-A (Baxter) (57.5%), 
Flexbumin 25% (Baxter) (40%), and DMSO (2.5%). iPSC derived MSCs used in these 
experiments were between passage 3 and 5.   Fourteen ex-vivo ECMO experiments were 
undertaken, divided as follows; circuits injected with 40 x 106 MSCs, circulated for 4 hours or 
until flow reached 0 L min-1 (n=4), circuits injected with 20 x 106 MSCs, circulated for 4 hours 
or until flow decreased by 25% from baseline (n=4), and control circuits, circulated for 4 hours 
(n=6). When physiological conditions were obtained (PaO2 ≥ 80 mmHg, PaCO2 30-50 mmHg), 
MSCs in vehicle were thawed to room temperature (>95% viability), agitated to eliminate 
clumping, and then immediately administered to the circuit, after the oxygenator and before 
the pump head, by slow injection over 30 seconds.  
  Whole blood samples were collected from the circuit at 30 seconds, 15, 30, 60, 120, and 240 
minutes. Erythrocytes were lysed, and residual cells were washed as described previously (6). 
Fc receptors were blocked using Human TruStain FCx (Biolegend, USA), and, MSCs were 
stained with mouse anti-human monoclonal antibodies: CD45-PECy7 (Biolegend), CD73-
PerCP, CD90-APC, and CD105-FITC (Abcam, UK), according to the manufacturer's protocol. 
Precision Count Beads (Biolegend) were then added to determine the fate of circulating MSCs, 
quantified using a two laser FACSCanto I flow cytometer (BD Biosciences, USA). 
  After termination of each experiment, oxygenators were flushed with 1000 mL 0.9% NaCl, 
perfused with 500 mL paraformaldehyde (Merck, Germany) and rinsed again with 1000 mL 
0.9% NaCl. Samples of the heat and gas exchange fibers were then retrieved.   
  For immunohistochemistry analysis, fiber sections were blocked for 2 hours in PBS 
containing 2% HISS (Sigma, Australia) and 0.5% triton X-100 (Sigma). Samples were 
incubated overnight at 4 ˚ C with primary antibodies: mouse Ab to CD105-FITC (Abcam, 1:10), 
or mouse Ab to CD90-PE (Abcam, 1:50) and rabbit antibody to β1 tubulin-488 conjugated 
(Abcam, 1:50). The fibres were washed with PBS followed by 1 hour incubation with 
secondary antibodies to boost the fluorescent signal followed by additional PBS washes. 
Images were acquired with a widefield Nikon deconvolution (TiE) microscope, and confocal 
z-stacks were acquired with Zeiss LSM710 AiryScan.    
Results 
  In all circuits to which MSCs were administered, blood flow through the ECMO oxygenator 
decreased by at least 25% within 4 hours, with a corresponding increase in the trans-oxygenator 
pressure gradient (Table 1). When 40 x 106 MSCs were administered, flow was reduced to < 
1.5 L min-1 in all circuits by 4 hours, and in one case within 30 minutes. ACT was maintained 
≥ 180 s throughout all experiments. Microscopy of deconstructed oxygenators demonstrated 
the widespread adherence of MSCs to plastic fibers (Figure 1).   
Discussion 
  This is the first study to directly address the feasibility of MSC therapy during ECMO. Our 
data suggest that intravascular administration of MSCs during ECMO may have important 
consequences for oxygenator function, as well as for their efficacy as a therapy for severe 
ARDS in this setting. This may have occurred due to the characteristic plastic adhesiveness of 
MSCs. A limitation of our study is that we did not assess gas exchange across the oxygenator. 
  MSC use during ECMO has been described previously but has either been administered 
before the commencement of ECMO (7), by intra-tracheal administration (8), or during a pause 
in flow (4). These methods of administration may not always be possible in severely ill ARDS 
patients who are reliant on continuous high flow ECMO for oxygenation. 
  At a circuit concentration of 48 - 95 x 103 MSCs mL-1, our study may have underestimated 
the effect of MSCs on oxygenator performance. Previous studies in ARDS have used up to 10 
x 106 MSCs kg-1 (1), which assuming an average blood volume of 70 mL kg-1 (9) and equal 
distribution, would result in a higher circulating cell concentration (approximately 143 x 103 
MSCs mL-1). This must be weighed against the possibility that indirect intravascular 
administration, peripherally or after the membrane oxygenator, may reduce the number of 
MSCs reaching the oxygenator surface, most likely as a result of entrapment in the 
pulmonary circulation. These data also support further investigation of MSC therapy during 
extracorporeal carbon dioxide removal (ECCO2R) or cardiopulmonary bypass, both of which 
share functionally similar membrane gas exchange devices with ECMO (10). 
  Alternative routes of administration, such as intra-bronchial, may have advantages in the 
setting of ECMO, when prolonged bronchoscopy is possible. This should be evaluated in any 
future study. In light of these results, further investigations using MSCs in ECMO should 
explore safety considerations in an intact animal model before progression to clinical trials.  
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 40 x 106 IPSC-MSCs 
(n=4) 
20 x 106 IPSC-MSCs* 
(n=4) 
Control  
(n=6) 
 
Time to 25% decrease in blood flow (minutes ± SE) 
 
68 ± 32 
 
99 ± 21 
 
- 
 
Time to 50% decrease in blood flow (minutes ± SE) 
 
 
85 ± 39 
 
- 
 
- 
Blood flow at 2000 rpm (L min-1 ± SE) 
 
     30 s 4.05 ± 0.02 4.04 ± 0.02 44.03 ± 0.05 
     15 min 3.79 ± 0.35 4.01 ± 0.04 4.03 ± 0.05 
     30 min 2.83 ± 0.98 4.12 ± 0.07 3.98 ± 0.06 
     60 min  1.94 ± 1.14 3.95 ± 0.20 4.12 ± 0.03 
     120 min  1.39 ± 0.92  4.09 ± 0.05 
     240 min 0.60 ± 0.35  4.12 ± 0.03 
Trans-oxygenator pressure gradient (mmHg ± SE) 
 
     30 s  20 ± 6 21 ± 2  119 ± 3 
     15 min 27 ± 12 21 ± 3 21 ± 2 
     30 min 51 ± 24 22 ± 3 25 ± 4 
     60 min  555 ± 31  28 ± 4 24 ± 3 
     120 min  50 ± 18  225 ± 4 
     240 min 101 ± 9  21 ± 4 
MSCs detectable in blood (cells µL-1 ± SE) 
 
     30 s  21.8 ± 1.9   
     30 min 9.4 ± 4.2   
     60 min  6.9 ± 3.4   
     120 min  4.1 ± 3.8   
     240 min  0.3 ± 0.2   
 
Table 1. Conditions during ex-vivo ECMO  
* Circuits terminated after a 25% reduction in blood flow (3 L min-1), performed to optimise conditions for 
microscopy. – Did not occur.  
 
 
  
Figure 1. ECMO oxygenator fibres after the administration of iPSC-derived human 
MSCs. (A) Wide field microscopy of CD105-stained MSCs (green) with a bright field overlay, of a 
section of polyurethane (PU) heat exchange fibres. MSCs can be seen adherent between adjacent fibre 
strands. (B) A confocal image of a MSC bridging two PU fibres. (A-B) DAPI-stained nuclei (blue) 
(C) A sample of polymethlpentene (PMP) gas exchange fibres, taken from the core of the oxygenator 
bundle and stained for CD105. (D) A similar section of PMP gas exchange taken from the periphery 
of the oxygenator and stained for CD90 with DAPI-stained nuclei.     
 
